Abstract
Alzheimer’s disease (AD) biomarkers represent several neurodegenerative processes, such as synaptic dysfunction, neuronal inflammation and injury, as well as amyloid pathology. We performed an exome-wide rare variant analysis of six AD biomarkers (β-amyloid, total/phosphorylated tau, Nfl, YKL-40, and Neurogranin) to discover genes associated with these markers. Genetic and biomarker information was available for 480 participants from two studies: EMIF-AD and ADNI. We applied a principal component (PC) analysis to derive biomarkers combinations, which represent statistically independent biological processes. We then tested whether rare variants in 9,576 protein-coding genes associate with these PCs using a Meta-SKAT test. We also tested whether the PCs are intermediary to gene effects on AD symptoms with a SMUT test. One PC loaded on Nfl and YKL-40, indicators of neuronal injury and inflammation. Three genes were associated with this PC: IFFO1, DTNB and NLRC3. Mediation tests suggest, that these genes also affect dementia symptoms via inflammation/injury. We also observed an association between a PC loading on Neurogranin, a marker for synaptic functioning, with GABBR2 and CASZ1, but no mediation effects. The results suggest that rare variants in IFFO1, DTNB and NLRC3 heighten susceptibility to neuronal injury and inflammation, potentially by altering cytoskeleton structure and immune activity disinhibition, resulting in an elevated dementia risk. GABBR2 and CASZ1 were associated with synaptic functioning, but mediation analyses suggest that the effect of these two genes on synaptic functioning is not consequential for AD development.
Competing Interest Statement
FB reports other from Neurology, other from Radiology, other from MSJ, other from Neuroradiology, personal fees from Springer, personal fees from Biogen, grants from Roche, grants from Merck, grants from Biogen, personal fees from IXICO Ltd, grants from IMI EU, grants from GE Healthcare, grants from UK MS Society, grants from Dutch Foundation MS Research, grants from NWO, grants from NIHR, personal fees from Combinostics, outside the submitted work; HZ has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. SL is currently an employee of Janssen Medical Ltd (UK), a cofounder of Akrivia Health Ltd (UK) and within the past 5 years has filed patents related to biomarkers unrelated to the current work and advised or given lectures for Merck, Optum Labs and Eisai as well as having received grant funding from multiple companies as part of EU IMI programmes and from Astra Zeneca. JP received consultation honoraria from Nestle Institute of Health Sciences, Ono Pharma, OM Pharma, and Fujirebio, unrelated to the submitted work. SE has served on scientific advisory boards for Biogen, Danone, icometrix, Novartis, Nutricia, Roche and received unrestricted research grants from Janssen Pharmaceutica and ADx Neurosciences (paid to institution). The others authors declare that there is no conflict of interest
Funding Statement
EMIF The authors thank the participants and families who took part in this research. The authors would also like to thank all people involved in data and sample collection and/or logistics across the different centres. Funding: The present study was conducted as part of the EMIF-AD project, which has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372, EPAD grant no. 115736, and from the European Unions Horizon 2020 research and innovation programme under grant agreement No. 666992. Resources of which are composed of financial contribution from the European Unions Seventh Framework Program (FP7/2007-2013) and EFPIA companies in-kind contribution. Research at VIB-UAntwerp was in part supported by the Research Foundation Flanders (FWO), and the University of Antwerp Research Fund, Belgium. FK is a supported by a PhD fellowship from the University of Antwerp Research Fund. The DESCRIPA study was funded by the European Commission within the fifth framework program (QLRT-2001-2455). The EDAR study was funded by the European Commission within the fifth framework program (contract no. 37670). The San Sebastian GAP study is partially funded by the Department of Health of the Basque Government (allocation 17.0.1.08.12.0000.2.454.01.41142.001.H). The Leuven cohort was funded by the Stichting voor Alzheimer Onderzoek (grant numbers #11020, #13007 and #15005). The Lausanne cohort was supported by grants from the Swiss National Research Foundation (SNF 320030_141179), Synapsis Foundation-Alzheimer Research Switzerland (grant number 2017-PI01). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimers Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjäanarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Unions Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. FB is supported by the NIHR biomedical research centre at UCLH ADNI Data collection and sharing for this project was funded by the Alzheimers Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimers Association; Alzheimers Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.;Cogstate;Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.;NeuroRx Research; Neurotrack Technologies;Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimers Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent for use of data, samples and scans was obtained from all participants before inclusion in EMIF AD MBD. The medical ethics committee at each site approved the study: Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Lausanne University Hospital (CHUV), Lausanne, Switzerland; Department of Psychiatry and Neuropsychology, University of Maastricht, The Netherlands; LENITEM - Laboratory of Epidemiology and Neuroimaging & Telemedicine, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, The Netherlands; Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Sweden; Department of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France; Fundacio ACE, Barcelona, Spain; The genetic counseling program for familial dementias (PICOGEN) at the Hospital Clinic, Barcelona, Spain; The outpatient clinics of the Sant Pau Memory Unit, Barcelona, Spain; University Hospitals Leuven, Belgium; Clinical Neurophysiology Unit, Department of Endocrinological and Metabolic Sciences, University of Genoa, Genoa, Italy; Division of Geriatric Psychiatry, Zentralinstitut fur Seelische Gesundheit, University of Heidelberg, Mannheim, Germany; Kingshill Research Centre, Swindon, UK; Department of Geriatrics, Hopital Broca, Paris, France; 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Department of Neurology, Kuopio University Hospital, Kuopio, Finland; Department of Geriatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; The Research Institute for the Care of Older People (RICE), Bath, UK; Department of Care of The Elderly, University of Bristol, Frenchay Hospital, Bristol, UK; Alzheimer Memorial Centre and Geriatric Psychiatry Branch, Dementia and Neuroimaging Section Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany; Institute Born-Bunge, ZNA Middelheim, University of Antwerp, Belgium; The PharmaCog study was reviewed and approved by the ethics committee of the coordinating site Brescia, Italy.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Data Availability
To comply with EU law and participant privacy, individual-level clinical data cannot be shared publicly, but can be requested via EMIF-AD.
